Altaris to Acquire Minaris Regenerative Medicine from Resonac

New York, NY – Altaris, LLC (collectively with its managed funds, “Altaris”) announced today that it has entered into a definitive agreement to acquire Minaris Regenerative Medicine (Minaris Regenerative Medicine, LLC in the United States, Minaris Regenerative Medicine Co., Ltd. in Japan, Minaris Regenerative Medicine GmbH in Germany, and along with its subsidiaries, “Minaris”) from Resonac Corporation, a subsidiary of Resonac Holdings Corporation (TYO: 4004) (“Resonac”). The acquisition is expected to close in the first quarter of 2025, subject to customary closing conditions.

Minaris is a cell therapy contract development and manufacturing organization (“CDMO”) that provides autologous and allogeneic manufacturing services for pharmaceutical and biotech customers globally. Founded in 1999 as Progenitor Cell Therapy, Minaris has been a pioneer in the field, including through its role in manufacturing pivotal study batches for Dendreon’s Provenge®, the first cell therapy approved for cancer treatment. Today, Minaris operates six facilities across the United States, Germany, and Japan and has more than 500 employees. Through its strategic footprint and manufacturing expertise, Minaris enables leading cell therapy companies to deliver life changing products to patients globally.

Advisors
J.P. Morgan served as financial advisor and Kirkland & Ellis LLP acted as legal counsel for Altaris. BofA Securities served as financial advisor and TMI Associates acted as legal advisor to Resonac.

About Altaris
Altaris is an investment firm with an exclusive focus on acquiring and building companies in the healthcare industry. Since its inception in 2003, Altaris has invested in more than 50 companies across a range of healthcare subsectors, with a consistent goal of delivering value to the healthcare system and generating attractive financial returns for investors. Altaris is headquartered in New York City and manages $10 billion of equity capital. For more information, please visit www.altariscap.com.